181 related articles for article (PubMed ID: 29354058)
1. SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis.
Dai S; Yan Y; Xu Z; Zeng S; Qian L; Huo L; Li X; Sun L; Gong Z
Front Pharmacol; 2017; 8():960. PubMed ID: 29354058
[TBL] [Abstract][Full Text] [Related]
2. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
3. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
4. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
5. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
6. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
7. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
8. A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis.
Wen YT; Wu AT; Bamodu OA; Wei L; Lin CM; Yen Y; Chao TY; Mukhopadhyay D; Hsiao M; Huang HS
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31561595
[TBL] [Abstract][Full Text] [Related]
9. Exosome-mediated transfer of MIF confers temozolomide resistance by regulating TIMP3/PI3K/AKT axis in gliomas.
Wei QT; Liu BY; Ji HY; Lan YF; Tang WH; Zhou J; Zhong XY; Lian CL; Huang QZ; Wang CY; Xu YM; Guo HB
Mol Ther Oncolytics; 2021 Sep; 22():114-128. PubMed ID: 34514093
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells
Dai S; Yan Y; Xu Z; Zeng S; Qian L; Huo L; Li X; Sun L; Gong Z
Front Pharmacol; 2019; 10():1358. PubMed ID: 31798454
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
12. PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway.
Shi L; Fei X; Wang Z; You Y
In Vitro Cell Dev Biol Anim; 2015 Nov; 51(10):1047-55. PubMed ID: 26170223
[TBL] [Abstract][Full Text] [Related]
13. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Alafate W; Wang M; Zuo J; Wu W; Sun L; Liu C; Xie W; Wang J
Pathol Res Pract; 2019 Nov; 215(11):152617. PubMed ID: 31563286
[TBL] [Abstract][Full Text] [Related]
14. Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway.
Xiong J; Guo G; Guo L; Wang Z; Chen Z; Nan Y; Cao Y; Li R; Yang X; Dong J; Jin X; Yang W; Huang Q
ACS Omega; 2021 Feb; 6(6):4289-4299. PubMed ID: 33644550
[TBL] [Abstract][Full Text] [Related]
15. Forkhead box protein O3a promotes glioma cell resistance to temozolomide by regulating matrix metallopeptidase and β-catenin.
Sun D; Yang S; Zhang X; Li S; Wang L; Chen J; Qiu C; Xu K
Oncol Lett; 2021 Apr; 21(4):328. PubMed ID: 33692860
[TBL] [Abstract][Full Text] [Related]
16. BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway.
Li M; Liang RF; Wang X; Mao Q; Liu YH
Oncol Lett; 2017 Dec; 14(6):6597-6603. PubMed ID: 29151909
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
19. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma.
Liu X; Chen J; Li W; Hang C; Dai Y
Transl Oncol; 2020 Jan; 13(1):70-78. PubMed ID: 31810002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
